人表皮生长因子受体2阳性乳腺癌患者中位点特异性标记89Zr-帕妥珠单抗的首次人体评估
该首次人体前瞻性临床试验纳入6例人表皮生长因子受体2(HER2)阳性转移性乳腺癌患者,评估位点特异性标记的89Zr-ss-帕妥珠单抗PET的安全性、生物分布与剂量学;最佳显像时间为给药后5-8天,未观察到毒性,平均有效剂量为0.54±0.03 mSv/MBq。
要点
- 89Zr-ss-帕妥珠单抗PET/CT可检测已知恶性肿瘤病灶,提示这些肿瘤病灶为HER2阳性。
- 最佳显像时间点为给药后5-8天,未观察到毒性。
- 平均有效剂量为0.54±0.03 mSv/MBq,与随机赖氨酸标记的89Zr-DFO-帕妥珠单抗和89Zr-DFO-曲妥珠单抗相当。
核心结论
- 本研究证明了89Zr-ss-帕妥珠单抗PET/CT的安全性、剂量学及潜在临床应用。
- 89Zr-ss-帕妥珠单抗可能比89Zr-DFO-帕妥珠单抗检测到更多病灶。
- 潜在临床应用包括实时评估HER2状态以指导活检和辅助治疗决策。
研究设计与样本
- 前瞻性临床试验纳入6例HER2阳性转移性乳腺癌患者。
- 帕妥珠单抗通过新型化学酶策略进行位点特异性去铁胺(DFO)修饰,随后用89Zr标记。
- 患者静脉注射74 MBq的89Zr-ss-帕妥珠单抗(总抗体20 mg),并在注射后1天、3-4天和5-8天进行PET/CT。
- 通过PET显像、全身探头计数和抽血评估药代动力学、生物分布和剂量学。
主要发现
- 89Zr-ss-帕妥珠单抗PET/CT用于评估HER2状态和异质性,以指导活检并在疾病进展时决定下一线治疗。
- 该放射免疫偶联物能够检测已知恶性肿瘤病灶,提示这些肿瘤病灶为HER2阳性。
- 最佳显像时间点为给药后5-8天,未观察到毒性。
- OLINDA剂量学估算显示,接受最高剂量的器官(均值±标准差)为肾脏(1.8±0.5 mGy/MBq)、肝脏(1.7±0.3 mGy/MBq)和心壁(1.2±0.1 mGy/MBq)。
- 89Zr-ss-帕妥珠单抗的平均有效剂量为0.54±0.03 mSv/MBq,与随机赖氨酸标记的89Zr-DFO-帕妥珠单抗和89Zr-DFO-曲妥珠单抗相当。
临床怎么用
- 作者认为,89Zr-ss-帕妥珠单抗PET/CT的潜在临床应用包括实时评估HER2状态以指导活检和辅助治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radioimmunoconjugates targeting human epidermal growth factor receptor 2 (HER2) have shown potential to noninvasively visualize HER2-positive tumors. However, the stochastic approach that has been traditionally used to radiolabel these antibodies yields poorly defined and heterogeneous products with suboptimal in vivo performance. Here, we describe a first-in-human PET study on patients with HER2-positive breast cancer evaluating the safety, biodistribution, and dosimetry of 89Zr-site-specific (ss)-pertuzumab PET, a site-specifically labeled radioimmunoconjugate designed to circumvent the limitations of random stochastic lysine labeling. Methods: Six patients with HER2-positive metastatic breast cancer were enrolled in a prospective clinical trial. Pertuzumab was site-specifically modified with desferrioxamine (DFO) via a novel chemoenzymatic strategy and subsequently labeled with 89Zr. Patients were administered 74 MBq of 89Zr-ss-pertuzumab in 20 mg of total antibody intravenously and underwent PET/CT at 1 d, 3-4 d, and 5-8 d after injection. PET imaging, whole-body probe counts, and blood draws were performed to assess the pharmacokinetics, biodistribution, and dosimetry. Results: 89Zr-ss-pertuzumab PET/CT was used to assess HER2 status and heterogeneity to guide biopsy and decide the next line of treatment at progression. The radioimmunoconjugate was able to detect known sites of malignancy, suggesting that these tumor lesions were HER2-positive. The optimal imaging time point was 5-8 d after administration, and no toxicities were observed. Dosimetry estimates from OLINDA showed that the organs receiving the highest doses (mean ± SD) were kidney (1.8 ± 0.5 mGy/MBq), liver (1.7 ± 0.3 mGy/MBq), and heart wall (1.2 ± 0.1 mGy/MBq). The average effective dose for 89Zr-ss-pertuzumab was 0.54 ± 0.03 mSv/MBq, which was comparable to both stochastically lysine-labeled 89Zr-DFO-pertuzumab and 89Zr-DFO-trastuzumab. One patient underwent PET/CT with both 89Zr-ss-pertuzumab and 89Zr-DFO-pertuzumab 1 mo apart, with 89Zr-ss-pertuzumab demonstrating improved lesion detection and higher tracer avidity. Conclusion: This study demonstrated the safety, dosimetry, and potential clinical applications of 89Zr-ss-pertuzumab PET/CT. 89Zr-ss-pertuzumab may detect more lesions than 89Zr-DFO-pertuzumab. Potential clinical applications include real-time evaluation of HER2 status to guide biopsy and assist in treatment decisions.
引用
- Yeh R, O'Donoghue JA, Jayaprakasam VS, et al. First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer. J Nucl Med. 2024. PMID: 38272704. doi:10.2967/jnumed.123.266392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。